Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China

Homologous recombination deficiency (HRD) is an approved predictive biomarker for Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer. However, the proportion of positive HRD in the real world and the relationship between HRD status and PARPi in Chinese ovarian cancer patients remain u...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Jing, Guo, Wenwen, Zhao, Qian, Cheng, Xianzhong, Xu, Xia, Zhou, Rui, Gu, Hongyuan, Chen, Chen, Chen, Xiaoxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779205/
https://www.ncbi.nlm.nih.gov/pubmed/35070965
http://dx.doi.org/10.3389/fonc.2021.746571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779205/
https://www.ncbi.nlm.nih.gov/pubmed/35070965
http://dx.doi.org/10.3389/fonc.2021.746571

Ejemplares similares